Leland Stanford Junior University

Cz Biohub Sf, Llc.

Neethan A Lobo

Michael F Clarke

Stephen R Quake

Maximilian Diehn

Piero D Dalerba

Jianbin Wang

Huiping Liu

Tomer Kalisky

Anne A Leyrat

Michael Rothenberg

Maider Zabala Ugalde

Jane Antony

Anne Leyrat

This disclosure provides data showing that LEFTY inhibits differentiation-promoting pathways such as BMP7/pSMAD5 in breast cancer cell lines, over and above its known role of inhibiting Nodal/pSMAD2. LEFTY competes with BMP7 to bind to its cell surface receptor BMPR2, leading to inhibition of pSMAD5. The LEFTY-BMPR2 interaction is dominant over BMP-BMPR2 in tumorigenic cells, resulting in diminished pSMAD status, whereas in non-tumorigenic cells, there is minimal LEFTY-BMPR2 interaction, increased BMP7-BMPR2 association, and elevated pSMAD. Compositions and methods for inducing or inhibiting expression and/or the activity of LEFTY and BMP proteins are described, which can be used in diagnosis and therapy of cancer and other conditions, and to promote proliferation of stem cells.

Compositions and methods for modulating left-right differentiation factor (LEFTY) and bone morphogenic factor (BMP)

Methods are provided for diagnosis and prognosis of disease by analyzing expression of a set of genes obtained from single cell analysis. Classification allows optimization of treatment, and determination of whether on whether to proceed with a specific therapy, and how to optimize dose, choice of treatment, and the like. Single cell analysis also provides for the identification and development of therapies which target mutations and/or pathways in disease-state cells.

Methods and systems for analysis of single cells

Growing community of inventors

Stanford, CA, United States of America

Neethan A Lobo